Bristol Myers Squibb Receives FDA Approval for Iberdomide in Relapsed/Refractory Multiple Myeloma

Bristol Myers Squibb today announced that the FDA has approved iberdomide plus dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least two prior therapies including an immunomodulatory agent and a proteasome inhibitor. In the Phase 3 SUCCESSOR-1 trial, iberdomide plus dexamethasone demonstrated a statistically significant improvement in progression-free survival versus pomalidomide plus dexamethasone. Iberdomide is a next-generation CELMoD with enhanced activity compared to current immunomodulatory drugs.